Robert A. Lafyatis, MD
Adjunct Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology (Arthritis)

MD, University of Cincinnati




A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy volunteers and Subjects with Systemic Lupus Erythematosus
04/09/2015 - 04/08/2020 (Co-PI)
PI: Christina Lam, MD
Biogen Idec


Scleroderma Clinical Repository (SCaR)
10/01/2014 - 09/30/2019 (PI)
Regeneron Pharmaceuticals, Inc.


A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2018 (Co-PI)
PI: Robert W. Simms, MD
Corbus Pharmaceuticals Holdings, Inc.


Scleroderma Workshop
02/01/2010 - 01/31/2018 (PI)
MedImmune, Inc.


ASSET: A Phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis - a double-blind, placebo-controlled, randomized controlled trial [IMI101-344]
03/31/2015 - 11/30/2017 (PI)
Regents of the Univ. of Michigan Bristol-Myers Squibb


Nox4 Inhibitor in Systemic Sclerosis
11/14/2014 - 11/13/2017 (PI)
Mistral Therapeutics, Inc.


Randomized, double-blind, placebo-controlled trial of IL1-Trap, Rilonacept, in Systemic Sclerosis-A Phase I/II Biomarker Trial
12/01/2011 - 04/30/2017 (PI)
Regeneron Pharmaceuticals, Inc.


A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis-A Phase I/II Biomarker and Safety Trial
04/02/2015 - 04/01/2017 (PI)
PRISM Pharma Co Ltd


A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 weeks total) of Epratuzamab in Systematic Lupus
06/01/2012 - 12/31/2016 (PI)
UCB Biosciences Inc.


A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with System
04/25/2012 - 12/31/2016 (PI)
Human Genome Sciences Inc


Showing 10 of 41 results. Show All Results



Yr Title Project-Sub Proj Pubs
2017 Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension 1R21AR069285-01A1
2017 International Workshop on Scleroderma Research 7R13AR053784-07
2017 Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis 2P50AR060780-06A1 25
2017 Administrative Core 2P50AR060780-06A1-6914 25
2017 Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics 2P50AR060780-06A1-6918 25
2015 Innate immunity in dermal fibrosis and systemic sclerosis 7R01AR051089-11 26
2015 NIAMS: CORT 5P50AR060780-05 25
2015 Rheumatic Diseases Research Core Centers 5P30AR061271-05 12
2015 Project 1 Biomarkers of disease activity and progression in systemic sclerosis 5P50AR060780-05-8686 25
2014 NIAMS: CORT 5P50AR060780-04 25
Showing 10 of 45 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Tabib T, Morse C, Wang T, Chen W, Lafyatis R. SFRP2/DPP4 and FMO1/LSP1 define major fibroblast populations in human skin. J Invest Dermatol. 2017 Oct 25. PMID: 29080679.
  2. Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, Spiera R, Simms RW, Varga J. Inhibition of ß-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82. J Invest Dermatol. 2017 Aug 12.View Related Profiles. PMID: 28807667.
  3. Sun Z, Wang T, Deng K, Wang XF, Lafyatis R, Ding Y, Hu M, Chen W. DIMM-SC: a Dirichlet mixture model for clustering droplet-based single cell transcriptomic data. Bioinformatics. 2017 Aug 02. PMID: 29036318.
  4. Derrett-Smith EC, Martyanov V, Chighizola CB, Moinzadeh P, Campochiaro C, Khan K, Wood TA, Meroni PL, Abraham DJ, Ong VH, Lafyatis R, Whitfield ML, Denton CP. Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. Arthritis Res Ther. 2017 Jul 04; 19(1):156. PMID: 28676069.
  5. Cao L, Lafyatis R, Burkly LC. Increased dermal collagen bundle alignment in systemic sclerosis is associated with a cell migration signature and role of Arhgdib in directed fibroblast migration on aligned ECMs. PLoS One. 2017; 12(6):e0180751. PMID: 28662216.
  6. Makino K, Makino T, Stawski L, Mantero JC, Lafyatis R, Simms R, Trojanowska M. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis. J Invest Dermatol. 2017 Aug; 137(8):1671-1681.View Related Profiles. PMID: 28433542.
  7. Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 2017 Mar 23; 9(1):27.View Related Profiles. PMID: 28330499; DOI: 10.1186/s13073-017-0417-1;.
  8. Man A, Correa JK, Ziemek J, Simms RW, Felson DT, Lafyatis R. Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis. Ann Rheum Dis. 2017 Aug; 76(8):1374-1380.View Related Profiles. PMID: 28213563; DOI: 10.1136/annrheumdis-2016-210534;.
  9. Xiong Y, Berrueta L, Urso K, Olenich S, Muskaj I, Badger GJ, Aliprantis A, Lafyatis R, Langevin HM. Stretching Reduces Skin Thickness and Improves Subcutaneous Tissue Mobility in a Murine Model of Systemic Sclerosis. Front Immunol. 2017; 8:124. PMID: 28261202; DOI: 10.3389/fimmu.2017.00124;.
  10. Li G, Larregina AT, Domsic RT, Stolz DB, Medsger TA, Lafyatis R, Fuschiotti P. Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis. J Invest Dermatol. 2017 May; 137(5):1042-1050. PMID: 28012718; DOI: 10.1016/j.jid.2016.11.037;.
Showing 10 of 145 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 145 publications over 28 distinct years, with a maximum of 16 publications in 2016

YearPublications
19881
19897
19908
19919
19921
19932
19944
19961
19971
19982
19992
20001
20024
20031
20043
20052
20066
20078
20083
20097
201010
20114
201210
20139
20146
20158
201616
20179
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Lafyatis's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department